HER2-low status discordance between primary and recurrent/metastatic breast cancer in a large-scale cohort

被引：0
|
作者：
Lin, Mingxi
Luo, Ting
Zhang, Hui
Yang, Wentao
Zhang, Jian
机构：
[1] Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
[2] Sichuan Univ, West China Hosp, Breast Dis Ctr, Chengdu, Sichuan, Peoples R China
[3] Northwestern Univ, Dept Prevent Med, Div Biostat, Chicago, IL USA
[4] Fudan Univ, Dept Breast & Urol Med Oncol, Shanghai Canc Ctr, Shanghai, Peoples R China
[5] Fudan Univ, Shanghai Med Coll, Shanghai, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2023年 / 41卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1021
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Differences in the Receptor Status between Primary and Recurrent Breast Cancer - The Frequency of and the Reasons for Discordance
    Heitz, Florian
    Barinoff, Jana
    du Bois, Ondra
    Hils, Rita
    Fisseler-Eckhoff, Annette
    Harter, Philipp
    Heitz, Julia
    Willenbrock, Klaus
    Traut, Alexander
    du Bois, Andreas
    ONCOLOGY, 2013, 84 (06) : 319 - 325
  • [42] Clinical outcomes in women with metastatic HER2-Low breast cancer in the real world
    Jiang, Changchuan
    Perimbeti, Stuthi
    Deng, Lei
    Shapiro, Charles L.
    Gandhi, Shipra
    CANCER RESEARCH, 2022, 82 (12)
  • [43] Trastuzumab Deruxtecan in HER2-Low Breast Cancer
    Carroll, Hailey K.
    Higgins, Michaela J.
    O'Reilly, Seamus
    NEW ENGLAND JOURNAL OF MEDICINE, 2022, 387 (12): : 1144 - 1144
  • [44] Changes in Estrogen Receptor, Progesterone Receptor and Her-2/neu Status with Time: Discordance Rates Between Primary and Metastatic Breast Cancer
    Broom, Reuben J.
    Tang, Patricia A.
    Simmons, Christine
    Bordeleau, Louise
    Mulligan, Anna Marie
    O'Malley, Frances P.
    Miller, Naomi
    Andrulis, Irene L.
    Brenner, Darren M.
    Clemons, Mark J.
    ANTICANCER RESEARCH, 2009, 29 (05) : 1557 - 1562
  • [45] Evolution of low HER2 expressions between primary and metastatic breast cancer
    Tarantino, P.
    Nicolo, E.
    Zagami, P.
    Giugliano, F.
    Trillo A, P.
    Marra, A.
    Trapani, D.
    Morganti, S.
    Mazzarella, L.
    Criscitiello, C.
    Esposito, A.
    Curigliano, G.
    ANNALS OF ONCOLOGY, 2020, 31 : S33 - S33
  • [46] Biology and Treatment of HER2-Low Breast Cancer
    Nicolo, Eleonora
    Tarantino, Paolo
    Curigliano, Giuseppe
    HEMATOLOGY-ONCOLOGY CLINICS OF NORTH AMERICA, 2023, 37 (01) : 117 - 132
  • [47] Clinical Significance of HER2-low Breast Cancer
    Zaiem, Fadi
    AbuJamea, Asem
    Kheil, Mira
    Numi, Anna
    Abbas, Omar
    Awada, Sanaa
    Almsaddi, Ragad
    Al-Juburi, Saleh
    Larson, Lauren
    Jain, Deepti
    AlSaghir, Maya
    Jang, Hyejeong
    Kim, Seongho
    Bandyopadhyay, Sudeshna
    Jaiman, Sunil
    Ali-Fehmi, Rouba
    CANCER RESEARCH, 2024, 84 (09)
  • [48] HER2-Low Breast Cancer: a New Subtype?
    Chiara Corti
    Federica Giugliano
    Eleonora Nicolò
    Paolo Tarantino
    Carmen Criscitiello
    Giuseppe Curigliano
    Current Treatment Options in Oncology, 2023, 24 : 468 - 478
  • [49] HER2-low breast cancer: where are we?
    Molinelli, Chiara
    Jacobs, Flavia
    Marchio, Caterina
    Pitto, Francesca
    Cosso, Maurizio
    Spinaci, Stefano
    de Azambuja, Evandro
    Schettini, Francesco
    Agostinetto, Elisa
    Lambertini, Matteo
    BREAST CARE, 2022, 17 (06) : 533 - 544
  • [50] Epidemiology of HER2-low breast cancer in Lithuania
    Cesas, A.
    Poskiene, L.
    Valkiuniene, R. B.
    Radvinskiene, L.
    Lege, I.
    EUROPEAN JOURNAL OF CANCER, 2024, 200 : 103 - 104
12345